絞り込み

16545

広告

1083件中 121件~140件表示    検索結果をPubMedで見る PubMedで見る

HER3 signaling and targeted therapy in cancer.

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.

CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer.

A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?

Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.

Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer.

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer.

Osimertinib for the treatment of patients with mutation-positive non-small cell lung cancer.

Gastrointestinal: Afatinib-induced acute esophageal necrosis.

Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitor.

High-throughput functional evaluation of variants of unknown significance in ERBB2.

Adaptive Resistance to EGFR Targeted Therapy by Calcium Signaling in NSCLC Cells.

Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer.

Coexistence of three EGFR mutations in an NSCLC patient: A brief report.

[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].

Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.

Afatinib restrains K-RAS-driven lung tumorigenesis.

  1. 3
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8
  7. 9
  8. 10
  9. 11
  10. 12
Sort by
※並べ替えは表示に時間がかかります